Paydirt
Insider filing · TVTX

Roy D. Baynes sold $320K of Travere Therapeutics (TVTX)

Executed Jan 23 2025, disclosed Jan 23 2025, the same day.

Value, as filed
$320K
16,000 sh × $20.00
Executed
Jan 23 2025
the trade date, as filed
Disclosed
Jan 23 2025
0 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only

Returns are measured on stock purchases only.

The filer
RB Roy D. Baynes Director profile →

Roy D. Baynes (Director) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.8M of NTRA (12,780 sh across 8 lots, as filed), executed Nov 19 2025.

The name
TVTX Travere Therapeutics, Inc. TVTX · Healthcare · 74 filings in 24 months ticker →

Healthcare · Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→
Other filings by Roy D. Baynes in TVTX
TVTXSALE Travere Therapeutics, Inc. $225K
4,500 sh × $50.00
Exec Jun 12
Filed Jun 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $210K
4,500 sh × $46.65
Exec May 5
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $431K
9,750 sh × $44.22
Exec May 1
Filed May 4 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $1.4M
32,750 sh across 2 lots
Exec Apr 14
Filed Apr 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $330K
10,000 sh × $33.00
Exec Apr 6
Filed Apr 7 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $220K
10,000 sh × $22.00
Exec Feb 6 2025
Filed Feb 10 2025 · 5:30 PM ET